Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease: A Treatable Trait

Abstract

Abstract COPD remains to be a giant public health burden and is the third leading cause of death worldwide. The presence of eosinophilic inflammation indicates a distinct pathophysiologic phenotype in COPD with a differential risk profile and response to therapy. Blood eosinophilia, clinical judgement and other patient centred factors helps in developing individualized treatment plans for patients with COPD. Appropriate management of eosinophilic airway inflammation will have an impact on lung function decline and exacerbations, thereby causing significant improvement in morbidity and mortality associated with COPD.